With new app for FDA approval, Gilead aims for a hep C trifecta

Gilead Sciences ($GILD), already reaping billions from its duo of approved hepatitis C therapies, has submitted a third pill to the FDA. The combination therapy, which has the agency's breakthrough designation, promises to cure a wider range of patients with the virus. Report